2025
Consensus Guideline for the Management of Colorectal Cancer with Peritoneal Metastases
Schultz K, Bansal V, Wach M, Bhutiani N, Godley F, Waheed M, Buchheit J, Papai E, Campbell S, Schleimer L, Su D, Turaga K, Gunderson C, White M, Uppal A, Raghav K, Labow D, Sarpel U, Shergill A, Shen J, Eng C, Foote M, Baumgartner J. Consensus Guideline for the Management of Colorectal Cancer with Peritoneal Metastases. Annals Of Surgical Oncology 2025, 1-23. PMID: 40560497, DOI: 10.1245/s10434-025-17363-0.Peer-Reviewed Original ResearchManagement of colorectal cancerPeritoneal surface malignanciesCirculating tumor DNACRC-PMColorectal cancerPeritoneal metastasisConsensus guidelinesUpfront cytoreductive surgerySite of metastasisProspective multicenter trialOptimal treatment strategyAssess agreement levelsModified Delphi techniqueResultsThe overall levelClinical management pathwaysBackgroundThe peritoneumCytoreductive surgerySurface malignanciesSystemic therapyTumor DNAMulticenter trialRisk stratificationTreatment strategiesPathway blockWeak recommendationConsensus guideline for the management of colorectal cancer with peritoneal metastases
Schultz K, Bansal V, Wach M, Bhutiani N, Godley F, Wang J, Waheed M, Buchheit J, Papai E, Campbell S, Schleimer L, Su D, Turaga K, Gunderson C, White M, Uppal A, Raghav K, Labow D, Sarpel U, Shergill A, Shen J, Eng C, Foote M, Baumgartner J, Group P. Consensus guideline for the management of colorectal cancer with peritoneal metastases. Cancer 2025, 131: e35869. PMID: 40558054, DOI: 10.1002/cncr.35869.Peer-Reviewed Original ResearchConceptsManagement of colorectal cancerCRC-PMColorectal cancerPeritoneal metastasisConsensus guidelinesPeritoneal surface malignancy centersCirculating tumor DNA testingUpfront cytoreductive surgerySite of metastasisProspective multicenter trialOptimal treatment strategyAssess agreement levelsLevel of evidenceOverall level of evidenceClinical management pathwaysModified Delphi techniqueCytoreductive surgerySystemic therapyMulticenter trialRisk stratificationTreatment strategiesPathway blockWeak recommendationPathological featuresMetastasis
2023
Evaluating the diagnostic performance of 18F-fluciclovine for detection of recurrent brain metastases after radiation therapy: Results from a prospective phase 2 trial.
Kotecha R, Chiang V, Tom M, Nabavizadeh A, Zan E, Peddi S, Sulman E, Siegel B, Huang J, Brem S, Ware M, Kesari S, Parent E, Pope W, Holmes R, Chau A, Teoh E, Chao S, Aboian M. Evaluating the diagnostic performance of 18F-fluciclovine for detection of recurrent brain metastases after radiation therapy: Results from a prospective phase 2 trial. Journal Of Clinical Oncology 2023, 41: 2001-2001. DOI: 10.1200/jco.2023.41.16_suppl.2001.Peer-Reviewed Original ResearchRecurrent brain metastasesImage interpretation criteriaF-fluciclovine PETF-fluciclovine uptakeBrain metastasesF-fluciclovineRadiation therapyDiagnostic performanceHistopathological analysisSUV maxFirst prospective multicenter trialProspective phase 2 trialSolid tumor brain metastasesTumor brain metastasesPhase 2 trialProspective multicenter trialIndependent blinded readersFluciclovine uptakePost-MRIPrimary endpointSecondary endpointsMulticenter trialRadiation necrosisRecurrent tumorsFuture trialsEvaluating the feasibility of a multicenter teleneonatology clinical effectiveness trial
Fang J, Umoren R, Whyte H, Limjoco J, Makkar A, Behl S, Lo M, White L, Culjat M, Taylor J, Kathuria S, Webb M, Schad T, Shafranski S, Yankanah R, Herrin J, Demaerschalk B. Evaluating the feasibility of a multicenter teleneonatology clinical effectiveness trial. Pediatric Research 2023, 94: 1555-1561. PMID: 37208433, DOI: 10.1038/s41390-023-02659-2.Peer-Reviewed Original ResearchConceptsClinical effectiveness trialCommunity hospitalEffectiveness trialPilot studyRisk neonatesClinical trialsHealth outcomesNeonatal intensive care unitProspective multicenter trialIntensive care unitMulticenter clinical trialFeasibility scoreMulticenter trialPrimary outcomeCare unitEarly health outcomesTrial protocolMain trialTelemedicine consultationsHospitalTrialsNeonatesOutcomesResearch ConsortiumScores
2021
Central vein sign: A diagnostic biomarker in multiple sclerosis (CAVS-MS) study protocol for a prospective multicenter trial
Ontaneda D, Sati P, Raza P, Kilbane M, Gombos E, Alvarez E, Azevedo C, Calabresi P, Cohen JA, Freeman L, Henry RG, Longbrake EE, Mitra N, Illenberger N, Schindler M, Moreno-Dominguez D, Ramos M, Mowry E, Oh J, Rodrigues P, Chahin S, Kaisey M, Waubant E, Cutter G, Shinohara R, Reich DS, Solomon A, Sicotte NL, Cooperative N. Central vein sign: A diagnostic biomarker in multiple sclerosis (CAVS-MS) study protocol for a prospective multicenter trial. NeuroImage Clinical 2021, 32: 102834. PMID: 34592690, PMCID: PMC8482479, DOI: 10.1016/j.nicl.2021.102834.Peer-Reviewed Original ResearchConceptsCentral vein signDiagnosis of MSMultiple sclerosisDiagnostic biomarkersMcDonald criteriaVein signProspective multicenter trialCross-sectional studyNumerous cross-sectional studiesNorth American ImagingNeuroradiologist reviewMulticenter trialAtypical presentationMulticenter studyTypical presentationSectional studyStudy protocolClinical careMS lesionsCentral readersEcho-planar MRIDiagnostic criteriaMS misdiagnosisMRI biomarkersMajor cause
2020
Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer.
Klotz L, Pavlovich CP, Chin J, Hatiboglu G, Koch M, Penson D, Raman S, Oto A, Fütterer J, Serrallach M, Relle J, Lotan Y, Heidenreich A, Bonekamp D, Haider M, Tirkes T, Arora S, Macura KJ, Costa DN, Persigehl T, Pantuck AJ, Bomers J, Burtnyk M, Staruch R, Eggener S. Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer. Journal Of Urology 2020, 205: 769-779. PMID: 33021440, DOI: 10.1097/ju.0000000000001362.Peer-Reviewed Original ResearchConceptsGrade Group 2 diseaseProstate-specific antigen reductionGrade group 2Whole gland ablationTransurethral ultrasound ablationAntigen reductionMagnetic resonance imagingProstate cancerGroup 2Gland ablationMagnetic resonance imaging-guided transurethral ultrasound ablationGrade 3 adverse eventsResonance imagingTarget volumeEvidence of cancerUltrasound ablationIntermediate-risk diseaseRisk prostate cancerProspective multicenter trialMedian prostate volumeLocalized prostate cancerMedian treatment delivery timeTreatment delivery timeMagnetic resonancePrimary endpoint
2019
Local–regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial)
Bellon JR, Guo H, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis M, Wolff AC, Carey LA, Overmoyer BA, Partridge AH, Hudis CA, Krop I, Burstein HJ, Winer EP, Tolaney SM. Local–regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial). Breast Cancer Research And Treatment 2019, 176: 303-310. PMID: 31004299, DOI: 10.1007/s10549-019-05238-4.Peer-Reviewed Original ResearchConceptsHER2-positive breast cancerLocal-regional recurrenceDisease-free survivalEffective anti-HER2 therapyLRR-free survivalAnti-HER2 therapyBreast-conserving surgeryBreast cancerRadiation therapySystemic therapyHormone receptor-positive tumorsProspective multi-institutional studyHER2-negative diseaseHER2-positive diseaseNegative axillary nodesEffective systemic therapyProspective multicenter trialEarly-stage patientsKaplan-Meier methodReceptor-positive tumorsHER2-positive tumorsMulti-institutional studyFuture investigational effortsAdjuvant trastuzumabProtocol therapy
2016
Analysis of the Final DENALI Trial Data: A Prospective, Multicenter Study of the Denali Inferior Vena Cava Filter
Stavropoulos SW, Chen JX, Sing RF, Elmasri F, Silver MJ, Powell A, Lynch FC, Aal A, Lansky A, Muhs BE, Investigators F. Analysis of the Final DENALI Trial Data: A Prospective, Multicenter Study of the Denali Inferior Vena Cava Filter. Journal Of Vascular And Interventional Radiology 2016, 27: 1531-1538.e1. PMID: 27569678, DOI: 10.1016/j.jvir.2016.06.028.Peer-Reviewed Original ResearchConceptsDeep vein thrombosisInferior vena cava filterPulmonary embolismVena cava filtersFilter placementFilter retrievalIVC filtersCava filtersSymptomatic recurrent pulmonary embolismRate of PERetrievable inferior vena cava filtersFilter-related complicationsLobar pulmonary embolismProspective multicenter trialRecurrent pulmonary embolismLow complication rateSubsegmental pulmonary embolismFilter dwell timeTemporary indicationsPrimary endpointSecondary endpointsComplication rateVein thrombosisCaval filtrationMulticenter trialDoes Level of Response to SI Joint Block Predict Response to SI Joint Fusion?
Polly D, Cher D, Whang PG, Frank C, Sembrano J. Does Level of Response to SI Joint Block Predict Response to SI Joint Fusion? The International Journal Of Spine Surgery 2016, 10: 4. PMID: 26913224, PMCID: PMC4752015, DOI: 10.14444/3004.Peer-Reviewed Original ResearchSIJ blockSIJ fusionPain improvementSIJ painPain reductionSIJ dysfunctionOswestry Disability Index scoresAverage pain reductionDisability Index scoresProspective multicenter trialSI joint fusionSacroiliac joint dysfunctionODI scoresPain reliefMulticenter trialJoint dysfunctionAcute improvementODI reductionPhysical examSubgroup analysisPredict responseJoint fusionPainBeneficial procedureStringent selection criteria
2008
Intensive Chemotherapy Followed by Hematopoietic Stem-Cell Rescue for Refractory and Recurrent Primary CNS and Intraocular Lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire
Soussain C, Hoang-Xuan K, Taillandier L, Fourme E, Choquet S, Witz F, Casasnovas O, Dupriez B, Souleau B, Taksin AL, Gisselbrecht C, Jaccard A, Omuro A, Sanson M, Janvier M, Kolb B, Zini JM, Leblond V. Intensive Chemotherapy Followed by Hematopoietic Stem-Cell Rescue for Refractory and Recurrent Primary CNS and Intraocular Lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. Journal Of Clinical Oncology 2008, 26: 2512-2518. PMID: 18413641, DOI: 10.1200/jco.2007.13.5533.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBrain NeoplasmsBusulfanCombined Modality TherapyCyclophosphamideCytarabineEtoposideEye NeoplasmsFemaleHematopoietic Stem Cell TransplantationHumansLymphoma, Large B-Cell, DiffuseMaleMiddle AgedNeoplasm Recurrence, LocalProspective StudiesSalvage TherapySurvival RateThiotepaConceptsPrimary CNS lymphomaHematopoietic stem cell rescueStem cell rescueIntensive chemotherapyIntraocular lymphomaAutologous hematopoietic stem cell rescueMedian progression-free survival timeRecurrent primary CNS lymphomaProgression-free survival timeHigh-dose cytarabineMedian overall survivalTreatment-related deathsImmunocompetent adult patientsProspective multicenter trialFirst-line treatmentOverall survival probabilityPFS probabilityCNS lymphomaComplete remissionSalvage treatmentAdult patientsOverall survivalPartial responseRefractory diseaseMulticenter trial
2004
Influence of admission and discharge aspirin use on survival after primary coronary angioplasty for acute myocardial infarction
Kandzari DE, Tcheng JE, Grines CL, Cox DA, Stuckey T, Griffin JJ, Turco M, Garcia E, Carroll JD, Fahy M, Lansky AJ, Mehran R, Stone GW, Investigators C. Influence of admission and discharge aspirin use on survival after primary coronary angioplasty for acute myocardial infarction. The American Journal Of Cardiology 2004, 94: 1029-1033. PMID: 15476618, DOI: 10.1016/j.amjcard.2004.06.060.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionAspirin useMyocardial infarctionPrimary percutaneous coronary interventionInfluence of admissionPrimary coronary angioplastyProspective multicenter trialPercutaneous coronary interventionTime of admissionCoronary interventionCoronary angioplastyMulticenter trialInfarctionAdmissionAngioplastyPatientsTrials
2002
Coronary heart disease stenting in small vessels versus balloon angloplasty study (CHIVAS): a randomized prospective multicenter trial
Muramatsu T, Iwasaki K, Inoue N, Horita Y, Tanaka T, Fujita N, Kamiya H, Namura M, Awano K, Murakami M, Ozaki Y, Lansky A. Coronary heart disease stenting in small vessels versus balloon angloplasty study (CHIVAS): a randomized prospective multicenter trial. Journal Of The American College Of Cardiology 2002, 39: 50. DOI: 10.1016/s0735-1097(02)80217-0.Peer-Reviewed Original ResearchProspective multicenter trialCoronary heart diseaseMulticenter trialHeart diseaseSmall vesselsDiseaseTrials
2000
Randomized Trial of Contrast Media Utilization in High-Risk PTCA
Davidson C, Laskey W, Hermiller J, Harrison J, Matthai W, Vlietstra R, Brinker J, Kereiakes D, Muhlestein J, Lansky A, Popma J, Buchbinder M, Hirshfeld J. Randomized Trial of Contrast Media Utilization in High-Risk PTCA. Circulation 2000, 101: 2172-2177. PMID: 10801758, DOI: 10.1161/01.cir.101.18.2172.Peer-Reviewed Original ResearchConceptsMajor adverse clinical eventsHospital major adverse clinical eventsPrimary end pointClinical eventsNonionic dimer iodixanolDimer iodixanolEnd pointLow-osmolar contrast agentsHigh-risk PTCAHospital clinical eventsThrombus-related eventsTotal clinical eventsDouble-blind trialAcute coronary syndromeHigh-risk patientsProspective multicenter trialAdverse clinical eventsCoronary artery interventionPTCA outcomeAngiographic successCoronary syndromeNovo lesionsArtery interventionMulticenter trialRandomized trials
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply